DPT Laboratories To Integrate With Confab - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DPT Laboratories To Integrate With Confab



The CDMOs DPT Laboratories, based in San Antonio, Texas, and Confab, based in Saint-Hubert, Quebec, have integrated under the leadership of Paul Johnson, group president and COO. Both DPT and Confab are owned by Renaissance Acquisition Holdings, a portfolio company of RoundTable Healthcare Partners, and represent its CDMO holdings.

The integration includes a rebranding and new logo for Confab, identifying it as a DPT company. A primary focus of the integration is for DPT’s sales and marketing team to introduce Confab’s experts in complex solid, semi-solid, and liquid dosage forms to new pharmaceutical industry clients, especially in the US market. The management teams for both companies will remain inplace, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson. DPT has additional R&D and manufacturing facilities in Lakewood, New Jersey.

Source: DPT Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here